The regulatory approaches to marijuana and tobacco in the United States are on decidedly different paths and, according to researchers from the U.S. and Australia, neither side appears interested in learning from the other.
“The two policy communities have shown very little interest in each other’s policy debates,” Wayne Hall and Lynn Kozlowski write in a new paper published in the journal Addiction.
Hall, the lead author, is a professor at the Centre for Youth Substance Abuse Research at the University of Queensland, Australia, and is an expert on marijuana and other drug use issues. Kozlowski is professor of community health and health behavior in the University at Buffalo’s School of Public Health and Health Professions and an expert on tobacco use and control.
Full story of marijuana and tobacco policy camps at Science Daily
The prevalence of smoking has remained fairly stable over the past decade after declining sharply for many years. To determine whether an increase in certain barriers to successful cessation and sustained abstinence may be contributing to this slowed decline, researchers at Columbia University’s Mailman School of Public Health analyzed changes in the prevalence of depression among current, former and never smokers in the U.S. The team found that depression appeared to have significantly increased in the U.S. from 2005 to 2013 among smokers, as well as among former and never smokers. While the prevalence of depression is consistently highest among smokers, the rate of increase in depression was most prominent among former and never smokers. The full study findings are published online in the journal Drug and Alcohol Dependence.
The research team, led by Renee Goodwin, PhD, in the Department of Epidemiology, analyzed data from the National Household Survey on Drug Use, an annual cross-sectional study of approximately 497, 000 Americans, ages 12 and over. The prevalence of past 12-month depression was examined annually among current (past 12-month), former (not past 12-month), and lifetime non-smokers from 2005 to 2013. The researchers further analyzed the data by age, gender, and household income.
Full story of depressions role in the tobacco epidemic at Science Daily
Suicide Prevention in American Indian and Alaska Native Communities
Suicide is a significant public health problem in the United States, with the rates of suicide within some populations being particularly high. This CEU course provides information about suicide clusters and responses in tribal communities; strength-based approaches to prevention, response, and recovery; existing and needed resources for prevention, response and recovery; and recommendations for tribal communities, and partners.
Anxiety Disorders and Developmental Attachment
Anxiety disorders represent a common but often debilitating form of psychopathology in both children and adults. This advanced CEU course presents a model of the influence of attachment relationships on the development of stress regulation strategies and discusses the role those relationships play in the development and maintenance of anxiety disorders, particularly the neurobiological alterations that underpin them.
Health Consequences of Tobacco
The epidemic of smoking-caused disease in the twentieth century ranks among the greatest public health catastrophes. This CEU course provides data on the numerous health effects resulting from smoking and exposure to second-hand smoke, and details public health trends in tobacco use. Strategies and effective interventions with the potential to eradicate the death and disease caused by the tobacco epidemic are also examined.
For more on these new courses and many more, visit Quantum Units Education
If a tobacco company changes a label for a product, the Food and Drug Administration (FDA) cannot consider it a new product for regulatory purposes, a federal judge ruled this week.
U.S. District Judge Amit Mehta said changing the quantity of a product in packaging does make it a new tobacco product, and requires FDA approval, according to the Winton-Salem Journal.
The three biggest tobacco manufacturers, Altria, Lorillard and Reynolds-American, sued the FDA and the Department of Health and Human Services in 2015 over new packaging rules.
Full story of tobacco label change at drugfree.org
The Food and Drug Administration (FDA) on Thursday announced it is extending its oversight to all tobacco products, including e-cigarettes, Reuters reports. The agency will ban sales of e-cigarettes, cigars, pipe tobacco and hookah tobacco to people under age 18.
Companies will be required to submit all tobacco products to the FDA for regulatory review. They will have to provide the agency with a list of product ingredients and place health warnings on their product packages and in ads.
The move allows the agency “to improve public health and protect future generations from the dangers of tobacco use through a variety of steps, including restricting the sale of these tobacco products to minors nationwide,” the FDA said in a statement.
Full story of FDA extending oversight on tobacco and e-cigarettes at drugfree.org